Company intelligence / Profile preview

Wockhardt Suisse

Ownership: Private
Development stage: Other

Overview

Wockhardt Suisse AG is a Switzerland-based pharmaceutical company incorporated in December 2025 as a step-down subsidiary of Wockhardt Limited, operating under Wockhardt Bio AG. The company serves as a key corporate and commercial vehicle for Wockhardt's global innovative pipeline, particularly in the United States and Europe. Through its subsidiary Wockhardt Suisse USA LLC, the company holds the US FDA approval for Zaynich (cefepime and zidebactam), a novel intravenous combination antibiotic approved in May 2026 for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis. Wockhardt Suisse AG is positioned to support the commercialization and distribution of Wockhardt's advanced anti-infective and biopharmaceutical portfolio globally.

Therapeutic areas: Infectious DiseasesNephrology
Modalities: Small molecule
Industry: Pharma

Beyond the preview

Go deeper on Wockhardt Suisse.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wockhardt Suisse.

Explore the full profile